- FDA may revise approval path to avoid some procedures abused by pharmaceutical companies
- Bayer terminates $670 million CAR-T partnership with Atara after patient death
- How much do cancer patients pay for CAT-T immunotherapy?
- Highly pathogenic bird flu outbreak: Watch out for ‘super-spreader’ bird species
- CanSino’s COVID-19 vaccine is included in WHO’s emergency use list (EUL)
- Switchable drug and spinal fluid trials may cure Alzheimer’s disease
Global overview of CAR-T patents
Global overview of CAR-T patents. A article counts 15,718 patents, excludes CAR-NK, TCR-T and duplicate records, and finally analyzes 12,431 CAR-T patents, belonging to 2,783 patent families.
1: Top 20 inventors (number of patents)
Carl H. June in the United States ranked first with 562 patents (44 series), and Martin Pule (493 in 61 families) and Shaun Cordoba (279 in 41 families) in the United Kingdom ranked second and third respectively. The fourth and fifth are French. Inventors with more than 200 patents are covered by the United States, Britain and France.
2: Top 20 patent assignees (number of patents)
Commercial companies dominate, accounting for 61% of the total, universities and hospitals accounting for 25%, non-profit organizations accounting for 13%, and individuals accounting for 1%. In the top 20, France, Switzerland and China each have one place, the United Kingdom has two places, and the rest are the United States. The University of Pennsylvania has the most, followed by BMS (Bristol Myers Squibb).
3: Patent institutions and regional cooperation
Generally speaking, the cooperation between Europe and the United States (the United States) is grid-like, and Asia (China) lacks cooperation between countries and institutions.
The cooperation of various parties in CAR-T development is different from the traditional model. After 2000, the cooperation between industry and academia gradually heated up. Commercial companies in the CAR-T field and non-profit institutions (universities/research institutes) were connected through affiliated hospitals. Cooperation, such as Memorial Sloan-Kettering Cancer Center and Eureka Therapeutics, U.S. Health and Human Services Center and Gilead Sciences, University of London and Autolus Therapeutics, university research institutes can also benefit through cooperation with commercial companies, and later the cooperation model also changed from the traditional Simple research or transfer of technological achievements has begun to shift to a cooperative model of resource sharing/cooperative research and development/joint patents. China has the second largest number of CAR-T patents in the world. There are 15 internationally cooperatively assigned patent families. Take Germany as an example. Its total patents are few and there are 10 internationally cooperatively assigned patents.
Detailed patent cooperation (blue is China), the overall pattern of China: one-to-one pairwise cooperation.
4: The trend of CAR-T patent publication
Generally speaking, 2017 is the first year of CAR-T. From the perspective of patent publication, CAR-T has entered rapid growth in 2015, mainly due to Novartis Gilead’s Kite Pharma and BMS’s JunoTherapeutics in 2014 and 2015 respectively. FDA breakthrough designation. In addition, Novartis announced its CD19CAR-T Phase II results in relapsed and refractory ALL at the 2015 ASH conference, with CR 92% and 93%.
5: CAR-T patents mainly cover the regional distribution of targets
The patent coverage targets are generally consistent with clinical research, and the subtle differences may guide future CAR-T development. For example, the BCMA target, which ranks second in the total number of patents in the world, is currently far behind CD19 in clinical research. (The relatively fixed time from R&D to application has not yet finished. After several BCMA-CAR T are advanced, maybe one or two years, maybe three to five years, and its clinical research should be comparable to CD19)
6: Milestones of CAR-T patent citation
Patent citation analysis, several important CAR-T patents, except for a few initial CAR-T veteran patents, from T preparation to CAR-T acquisition and inspection, to the final application of CAR -T related patents related to combination inhibitors (such as mTOR inhibitors); bispecific CAR-T; CAR basic research (improving efficacy and amplification, efficacy prediction biomarker, CAR expression method), etc., will be included in subsequent patents High frequency references.
(source:internet, reference only)